Project Grant R43GM156257
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$301K
Federal Agency
National Institute of General Medical Sciences
Awardee
E&E Bioclub LLC (G3QVKFNX6PZ5)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $350,000 to Cisterna Biologics, Inc. to develop a novel production and purification process for ultra-pure mRNA. The key objectives are to generate contaminant-free mRNA essential for high-dosage and frequent therapeutic applications, such as enzyme replacement and cancer immunotherapy. The approach involves developing...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $833,652 to the University of Connecticut to develop novel DNA-inspired biomaterials for effective intracellular delivery of messenger RNA (mRNA) therapeutics and research tools. The research aims to optimize the biointerface properties of Janus base nanoparticles (JBNPs) using computational molecular design and experimental validation,...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
The National Institute of General Medical Sciences (NIGMS) awarded a $963,619 Project Grant (CFDA 93.859) to Osem Fluidics Inc. on January 1, 2025 for a project titled "Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery". The project aims to develop 3D-printed microfluidic channel architectures to precisely control the structure and properties of lipid nanoparticles (LNPs) in order to enhance their transfection efficiency...
This Project Grant award, valued at $936,000.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) federal grant program. The goal of this project is to develop a platform called mRNADesigner, an integrated deep learning model to optimize the 5'UTR, codon usage, and 3'UTR of mRNA sequences simultaneously. This will enable users to design optimal mRNA sequences to enhance protein expression levels and...
The National Institute of General Medical Sciences (NIGMS) awarded a $298,530 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Epigenter, LLC in Providence, RI. The goal of this 1-year award, effective July 1, 2025, is to develop and characterize "self-delivering" epigenetic editor proteins that can modulate gene expression by targeted DNA demethylation, without requiring genetic transduction. The project will compare two different protein...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $658,165.00 to Triad National Security, LLC to conduct advanced research on the effects of ions on mRNA, ribosomes, and antibiotic-RNA interactions. The research aims to deepen the understanding of ribosome mechanism and mRNA regulation at the atomistic level, with a focus on the bacterial ribosome. Key areas of...
The National Institute of General Medical Sciences (NIGMS) awarded a $917,454 Project Grant under CFDA 93.859, Biomedical Research and Research Training, to Integral Molecular Inc. The grant supports the development of a novel Membrane Proteome Array (MPA) technology for specificity screening and profiling of biotherapeutics like monoclonal antibodies and CAR-T cell therapies. The MPA represents 93% of the human extracellular proteome expressed in native conformation, providing a more...
This $842,151 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an improved, low-endotoxin E. coli strain for the production of biological products such as recombinant proteins and plasmid DNA. The awardee, Scarab Genomics LLC, a biotechnology company in Madison, Wisconsin, will use genetic engineering techniques to substantially lower the level of contaminating endotoxin...